Type 2 Diabetes | Disease Landscape & Forecast | G7 | 2024
The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity of several key T2D brands such as the dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch and uptake of Eli Lilly’s first-in-class, glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist, Mounjaro, and other late-phase therapies will support the T2D market through 2033. Significant unmet need remains for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.
QUESTIONS ANSWERED
- What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?
- How has the launch of Eli Lilly’s tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic in the United States and Japan? How will the therapy be received in the European markets?
- How will the launch of nonbranded therapies affect the G7 T2D market?
- What do key opinion leaders think about emerging therapies such as Novo Nordisk’s insulin icodec and CagriSema?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of T2D by country with population-specific diagnosed and drug-treated rates.
- Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2033, segmented by brands / generics.
- Emerging therapies: Phase 3/PR: 5 drugs
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
KEY FEATURES
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
